07:00 , Jun 25, 2007 |  BioCentury  |  Strategy

Shire product sales

Shire product sales Product [Partner] Indication 2006 sales Adderall XR ADHD $863.6 Pentasa [Ferring] Ulcerative colitis (UC) $137.8 Replagal Fabry's disease $117.7 Carbatrol Epilepsy $68.3 Agrylin/Xagrid Thrombocythemia $60.8 Other Various $60.6 Calcichew [Nycomed] Osteoporosis $45.5...
07:00 , Sep 25, 2006 |  BioCentury  |  Strategy

Nycomed-Altana key products

Nycomed-Altana key products Nycomed-Altana key products Net sales for the top three products from Nycomed and Altana totaled E1.7 billion ($2.1 billion) in 2005. Nycomed has rights to pantoprazole from Altana in certain countries, while...
07:00 , Apr 25, 2005 |  BioCentury  |  Strategy

Shire-Transkaryotic pipeline

Shire-Transkaryotic pipeline Product Indication Status (Milestones) Company Adderall & Adderall XR Attention deficit hyperactivity disorder (ADHD) Mkt SHP Agrylin Thrombocythemia secondary to a myeloproliferative disorder Mkt SHP Calcichew Adjunct in osteoporosis Mkt in U.K. SHP/Nycomed...
08:00 , Jan 3, 2005 |  BioCentury  |  Finance

Value-driven in Europe

As in the U.S., there was little in the way of momentum investing in Europe last year, with value investors picking their shots to provide a decent 2004. This year looks to be more of...